Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 9/20 | 0.78 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.78 |
| ▸ | PSMB10 | P40306 | 9/20 | 0.70 |
| ▸ | PSMB9 | P28065 | 4/20 | 0.70 |
| ▸ | PSMB2 | P49721 | 10/20 | 0.65 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16228100 | 1.00 | PSMB8 (0.78) | PSMB8PSMB5PSMB10PSMB9PSMB2 | |
| SCHEMBL16118918 | 1.00 | PSMB8 (0.78) | PSMB8PSMB5PSMB10PSMB9PSMB2 | |
| SCHEMBL16228275 | 1.00 | PSMB8 (0.78) | PSMB8PSMB5PSMB10PSMB9PSMB2 | |
| SCHEMBL16118930 | 1.00 | PSMB8 (0.78) | PSMB8PSMB5PSMB10PSMB9PSMB2 | |
| SCHEMBL16227888 | 0.96 | PSMB8 (0.77) | PSMB8PSMB5PSMB10PSMB9PSMB2 | |
| SCHEMBL16228534 | 0.96 | PSMB8 (0.77) | PSMB8PSMB5PSMB10PSMB9PSMB2 | |
| SCHEMBL16118939 | 0.96 | PSMB8 (0.77) | PSMB8PSMB5PSMB10PSMB9PSMB2 | |
| SCHEMBL16118926 | 0.96 | PSMB8 (0.77) | PSMB8PSMB5PSMB10PSMB9PSMB2 | |
| SCHEMBL16119197 | 0.96 | PSMB8 (0.77) | PSMB8PSMB5PSMB10PSMB9PSMB2 | |
| SCHEMBL16119242 | 0.95 | PSMB8 (0.83) | PSMB8PSMB5PSMB10PSMB9PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-RE47302-E1 | Peptide epoxyketone immunoproteasome inhibitors | ONYX THERAPEUTICS INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-RE47302-E1 | Peptide epoxyketone immunoproteasome inhibitors | ONYX THERAPEUTICS INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-2970224-B1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2970224-B1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2014152134-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | PSMB8 489/4885PSMB5 511/4885PSMB10 750/4885 |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | PSMB8 489/4885PSMB5 511/4885PSMB10 750/4885 |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | PSMB8 489/4885PSMB5 511/4885PSMB10 750/4885 |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | PSMB8 489/4885PSMB5 511/4885PSMB10 750/4885 |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | PSMB8 489/4885PSMB5 511/4885PSMB10 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.